Semaglutide in Obesity: Unmet Needs in Men

Diabetes Ther. 2023 Mar;14(3):461-465. doi: 10.1007/s13300-022-01360-7. Epub 2023 Jan 7.

Mojca Jensterle^{1

2}, Manfredi Rizzo³, Andrej Janež^{4

5}

¹ Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia.
² Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia.
³ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Palermo, Italy.
⁴ Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia. andrej.janez@kclj.si.
⁵ Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia. andrej.janez@kclj.si.

No abstract available

Keywords: Anti-obesity medication; Body mass index; Glucagon-like peptide 1 receptor agonist; Men; Obesity; Semaglutide; Women.